297 related articles for article (PubMed ID: 7565947)
1. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
McKenzie R; Fried MW; Sallie R; Conjeevaram H; Di Bisceglie AM; Park Y; Savarese B; Kleiner D; Tsokos M; Luciano C
N Engl J Med; 1995 Oct; 333(17):1099-105. PubMed ID: 7565947
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.
Tennant BC; Baldwin BH; Graham LA; Ascenzi MA; Hornbuckle WE; Rowland PH; Tochkov IA; Yeager AE; Erb HN; Colacino JM; Lopez C; Engelhardt JA; Bowsher RR; Richardson FC; Lewis W; Cote PJ; Korba BE; Gerin JL
Hepatology; 1998 Jul; 28(1):179-91. PubMed ID: 9657111
[TBL] [Abstract][Full Text] [Related]
3. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax).
Lewis W; Griniuviene B; Tankersley KO; Levine ES; Montione R; Engelman L; de Courten-Myers G; Ascenzi MA; Hornbuckle WE; Gerin JL; Tennant BC
Lab Invest; 1997 Jan; 76(1):77-87. PubMed ID: 9010451
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic changes associated with fialuridine hepatotoxicity.
Kleiner DE; Gaffey MJ; Sallie R; Tsokos M; Nichols L; McKenzie R; Straus SE; Hoofnagle JH
Mod Pathol; 1997 Mar; 10(3):192-9. PubMed ID: 9071726
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro.
Semino-Mora C; Leon-Monzon M; Dalakas MC
Lab Invest; 1997 Apr; 76(4):487-95. PubMed ID: 9111511
[TBL] [Abstract][Full Text] [Related]
6. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.
Lange CM; Bojunga J; Hofmann WP; Wunder K; Mihm U; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):2001-6. PubMed ID: 19937695
[TBL] [Abstract][Full Text] [Related]
7. Falsely low calcium measurements after high volume plasma exchange in a patient with liver failure.
Miller JP; Mintz PD
Transfus Sci; 1994 Sep; 15(3):299-302. PubMed ID: 10161259
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial toxicity--new adverse drug effects.
Swartz MN
N Engl J Med; 1995 Oct; 333(17):1146-8. PubMed ID: 7565955
[No Abstract] [Full Text] [Related]
9. Severe toxicity of fialuridine (FIAU).
Lewis W; Perrino FW
N Engl J Med; 1996 Apr; 334(17):1136; author reply 1137-8. PubMed ID: 8598881
[No Abstract] [Full Text] [Related]
10. Mitochondrial injury. Lessons from the fialuridine trial.
Honkoop P; Scholte HR; de Man RA; Schalm SW
Drug Saf; 1997 Jul; 17(1):1-7. PubMed ID: 9258627
[TBL] [Abstract][Full Text] [Related]
11. Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
McGory RW; Ishitani MB; Oliveira WM; Stevenson WC; Dickson RC; Caldwell SH; Pruett TL
Transplant Proc; 1995 Feb; 27(1):1213-4. PubMed ID: 7878854
[No Abstract] [Full Text] [Related]
12. Severe toxicity of fialuridine (FIAU).
Gordon M
N Engl J Med; 1996 Apr; 334(17):1136-7; author reply 1137-8. PubMed ID: 8598883
[No Abstract] [Full Text] [Related]
13. Deaths in US fialuridine trial.
Brahams D
Lancet; 1994 Jun; 343(8911):1494-5. PubMed ID: 7911188
[No Abstract] [Full Text] [Related]
14. Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU).
Colacino JM
Antiviral Res; 1996 Mar; 29(2-3):125-39. PubMed ID: 8739593
[TBL] [Abstract][Full Text] [Related]
15. Lactic acidosis associated with stavudine administration: a report of five cases.
Mokrzycki MH; Harris C; May H; Laut J; Palmisano J
Clin Infect Dis; 2000 Jan; 30(1):198-200. PubMed ID: 10619755
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection.
Stevenson W; Gaffey M; Ishitani M; McCullough C; Dickson R; Caldwell S; Lobo P; Pruett T
Transplant Proc; 1995 Feb; 27(1):1219-21. PubMed ID: 7878856
[No Abstract] [Full Text] [Related]
17. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B.
Honkoop P; de Man RA; Scholte HR; Zondervan PE; Van Den Berg JW; Rademakers LH; Schalm SW
Hepatology; 1997 Jul; 26(1):211-5. PubMed ID: 9214472
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
Tillmann HL; Hadem J; Leifeld L; Zachou K; Canbay A; Eisenbach C; Graziadei I; Encke J; Schmidt H; Vogel W; Schneider A; Spengler U; Gerken G; Dalekos GN; Wedemeyer H; Manns MP
J Viral Hepat; 2006 Apr; 13(4):256-63. PubMed ID: 16611192
[TBL] [Abstract][Full Text] [Related]
19. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
20. A preliminary trial of lamivudine for chronic hepatitis B infection.
Dienstag JL; Perrillo RP; Schiff ER; Bartholomew M; Vicary C; Rubin M
N Engl J Med; 1995 Dec; 333(25):1657-61. PubMed ID: 7477217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
